Aethlon Medical, Inc. (AEMD)
| Market Cap | 1.49M -51.8% |
| Revenue (ttm) | n/a |
| Net Income | -7.15M |
| EPS | -53.06 |
| Shares Out | 474.11K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 71,462 |
| Open | 3.020 |
| Previous Close | 3.020 |
| Day's Range | 3.000 - 3.270 |
| 52-Week Range | 2.625 - 137.000 |
| Beta | 1.44 |
| Analysts | Hold |
| Price Target | 16.25 (+415.87%) |
| Earnings Date | Aug 13, 2026 |
About AEMD
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AEMD stock is "Hold." The 12-month stock price target is $16.25, which is an increase of 415.87% from the latest price.
News
Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026
SAN DIEGO, Aug. 5, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, tod...
Aethlon Medical trading halted, news pending
19:50 EDT Aethlon Medical (AEMD) trading halted, news pending
Aethlon Medical Transcript: Emerging Growth Conference
Hemopurifier, a blood filtration device, is showing promising early results in oncology trials by reducing harmful particles and supporting immune function. The company is well-financed, focused on completing its current trial, and aims to expand its platform to multiple disease areas.
Aethlon Medical announces results from Hemopurifier trial in Australia
Aethlon Medical (AEMD) announced that patients in the second cohort of its Australian oncology feasibility study demonstrated biological changes consistent with those previously observed in the first ...
Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®
Second cohort findings consistent with previously reported observations; independent statistical analysis planned following completion of all three patient cohorts SAN DIEGO, July 13, 2026 /PRNewswire...
Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
SAN DIEGO, July 6, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, tod...
Aethlon Medical Slides
Aethlon Medical has posted slides in relation to its latest quarterly earnings report, which was published on July 3, 2026.
Aethlon Medical Registration statement: Registration filing
Aethlon Medical filed a registration statement on July 1, 2026, providing details about a securities offering with the SEC.
Aethlon Medical Registration statement: Registration filing
Aethlon Medical filed a registration statement on July 1, 2026, providing details about a securities offering with the SEC.
Aethlon Medical announces publication demonstrating potential of Hemopurifier
Aethlon Medical (AEMD) announced publication of new peer-reviewed research in the International Journal of Molecular Sciences demonstrating that patients with Long COVID exhibit significantly increase...
Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®
Peer-reviewed study identifies altered extracellular vesicles in Long COVID and provides additional scientific rationale for evaluating the Hemopurifier® as a potential treatment SAN DIEGO, June 26, 2...
Aethlon Medical files to sell 6M shares of common stock, warrants
Maxim Group is exclusive placement agent in connection with the offering.
Aethlon Medical Registration statement: Registration filing
Aethlon Medical filed a registration statement on June 22, 2026, providing details about a securities offering with the SEC.
Aethlon Medical Slides: Corporate presentation
Aethlon Medical has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
Aethlon Medical Earnings Call Transcript: Q4 2026
Advanced clinical and preclinical programs for the Hemopurifier platform, reduced operating expenses by 21.9% year-over-year, and improved net loss to $7.2 million. Clinical trials progressed with positive safety and early efficacy signals, and cash position was strengthened.
Aethlon Medical Earnings release: Q4 2026
Aethlon Medical released its Q4 2026 earnings on June 10, 2026, summarizing the period's financial results.
Aethlon Medical Annual report: Q4 2026
Aethlon Medical has published its Q4 2026 annual report on June 10, 2026.
Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
Australian oncology study advances into Cohort 3 as enrollment continues Entered the third and final dosing cohort of the Australian oncology study, expanded the Hemopurifier intellectual property por...
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026
SAN DIEGO, June 2, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, tod...
Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness
SAN DIEGO, May 21, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, tod...
Aethlon Medical Transcript: Emerging Growth Conference 91
An Australian oncology trial is advancing to its final cohort after positive safety review, focusing on optimizing Hemopurifier treatments for patients unresponsive to leading immunotherapies. Data on immune and exosome changes are expected soon, with future plans for regulatory submission and larger studies.
Aethlon Medical Slides: Corporate presentation
Aethlon Medical has posted slides in relation to its latest quarterly earnings report, which was published on March 27, 2026.
Advancements in Novel Immunotherapeutics in The Oncology Battle
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - March 24, 2026) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at advancements in novel immun...
Aethlon Medical advances to final cohort in AEMD-2022-06 trial
Aethlon Medical (AEMD) announced that the independent Data Safety Monitoring Board overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of the second cohort par...
Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review
SAN DIEGO, March 24, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device fo...